The availability of Humira biosimilars potentially affects a vast number of patients and healthcare professionals. Our team of clinicians explored all of the different biosimilars set to enter the ...

Humira is used to treat certain inflammatory conditions. It’s mainly covered by Medicare Part D when self-administered or, more rarely, by Part B when administered by a doctor. Humira ...

AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...

AbbVie (NYSE: ABBV) recently dipped nearly 20% and is still down 14%, offering an enticing 3.7% forward yield. Here's what ...

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

The Institute for Clinical and Economic Review flagged five drugs whose prices were raised in 2023 with no evidence to ...

In an attempt to continue its I&I dominance beyond Humira, Skyrizi and Rinvoq, AbbVie is buying up another small autoimmune ...

Policy experts punched holes in drug companies' claims that the Medicare Drug Price Negotiation Program will stunt innovation ...

It might be 11:11 or 3:33. Maybe repeating numbers have made their way into other aspects of your life, such as a receipt that totaled $22.22. These may seem like mere coincidences ...

The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...

This was, of course, still driven by its blockbuster product Humira. Biotechnology is becoming more and more the leading technology within the pharmaceutical industry. Seven out of the ten most ...